Related Experiment Video
Updated: May 31, 2025
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in
Seiichi Hayato1, Lora Hamuro2, Toshio Shimizu3,4
1Eisai Co. Ltd., Tokyo, Japan.
Abstract:
The first-in-human, Phase 1 Study 101 showed antitumor activity and a tolerable safety profile of farletuzumab ecteribulin in Japanese patients with platinum-resistant ovarian and non-small cell lung cancer. A pharmacometric assessment evaluated farletuzumab ecteribulin pharmacokinetics and exposure-response (E-R) relationships for efficacy and safety to support dose optimization. Patients received 0.3-1.2 mg/kg of farletuzumab ecteribulin intravenously every 3 weeks. A pharmacokinetics (PK) model was developed and used for E-R analyses. Efficacy was assessed via tumor response and safety via known treatment-emergent adverse events (TEAEs) of farletuzumab ecteribulin, particularly pneumonitis/interstitial lung disease (ILD). Dosing scenarios were simulated to identify dosing that maximizes the probability of an objective response while minimizing the risk of ILD. The farletuzumab ecteribulin PK dataset included 1261 observations from 82 patients. The final model included an estimated population mean value for farletuzumab ecteribulin clearance of 0.0162 L/h. Body surface area (BSA) was a significant PK covariate and was included in the model. Body weight (BW) was associated with higher farletuzumab ecteribulin exposure. Using BW-based dosing, farletuzumab ecteribulin AUC (area under the serum concentration-time curve) was higher in patients with tumor response or stable disease versus patients with progressive disease and higher in patients with ILD and other TEAEs. Dosing simulations showed that BSA-based dosing (33 mg/m2) yielded similar tumor responses to BW-based dosing (0.9 mg/kg) and decreased ILD rates. This study showed that BW-based dosing resulted in higher risks of ILD events for patients with a high BW versus low BW, whereas BSA-based dosing is predicted to reduce this risk while maintaining clinical efficacy.
Insights
Farletuzumab ecteribulin shows antitumor activity in ovarian and lung cancer. Body surface area dosing may improve safety by reducing interstitial lung disease risk compared to body weight dosing.
Area of Science:
- Oncology
- Pharmacometrics
- Clinical Pharmacology
Background:
- Farletuzumab ecteribulin demonstrated antitumor activity and a tolerable safety profile in a Phase 1 study of Japanese patients with platinum-resistant ovarian and non-small cell lung cancer.
- Pharmacometric assessment is crucial for optimizing drug dosage by evaluating pharmacokinetic and exposure-response relationships.
Purpose of the Study:
- To evaluate the pharmacokinetics (PK) and exposure-response (E-R) relationships for farletuzumab ecteribulin's efficacy and safety.
- To support dose optimization for farletuzumab ecteribulin in Japanese patients with platinum-resistant cancers.
- To identify dosing strategies that maximize response probability while minimizing interstitial lung disease (ILD) risk.
Main Methods:
- Developed a population PK model using data from 82 patients treated with farletuzumab ecteribulin (0.3-1.2 mg/kg IV every 3 weeks).
- Conducted E-R analyses for efficacy (tumor response) and safety (treatment-emergent adverse events, particularly ILD).
- Simulated various dosing scenarios, including body weight (BW)-based and body surface area (BSA)-based dosing.
Main Results:
- Body surface area (BSA) was identified as a significant PK covariate. Body weight (BW) was associated with higher drug exposure.
- Higher farletuzumab ecteribulin exposure (AUC) correlated with better efficacy (tumor response/stable disease) and increased risk of ILD and other adverse events with BW-based dosing.
- BSA-based dosing (33 mg/m²) demonstrated comparable efficacy to BW-based dosing (0.9 mg/kg) but was predicted to reduce ILD rates, especially in patients with higher BW.
Conclusions:
- BSA-based dosing of farletuzumab ecteribulin is predicted to maintain clinical efficacy while potentially reducing the risk of ILD events compared to BW-based dosing.
- This approach may mitigate the increased risk of ILD observed with higher BW in BW-based dosing regimens.
- Pharmacometric modeling provides valuable insights for optimizing dosing strategies to balance efficacy and safety in cancer therapy.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
Related Concept Videos
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
01:14Compartment Models: Single-Compartment Model
01:17Clearance Models: Noncompartmental Models
The noncompartmental approach capitalizes on extensive sampling data, correlating the volume of distribution to systemic exposure and the administered dosage. This method enables...
01:20Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...